YLYu Li

Yu Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yu Li has a total of 14 co-authors. Here are the top co-authors by number of shared publications:

  • Caifeng Li

    Jiangxi Province Key Laboratory of Traditional Chinese Medicine Pharmacology, Institute of Traditional Chinese Medicine Health Industry, China Academy of Chinese Medical Sciences, Nanchang 330115, China

    1 shared publication
  • Fangbo Zhang

    Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, No. 16 Nanxiaojie, Dongzhimennei Ave, Beijing 100700, China

    1 shared publication
  • Huamin Zhang

    Institute of Basic Theory for Chinese Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, China

    1 shared publication
  • Jing Yan

    Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, No. 16 Nanxiaojie, Dongzhimennei Ave, Beijing 100700, China

    1 shared publication
  • Junxian Cao

    Experimental Research Center, China Academy of Chinese Medical Sciences, Beijing 100700, China

    1 shared publication
  • Peng Chen

    Experimental Research Center, China Academy of Chinese Medical Sciences, Beijing, China

    1 shared publication

Latest Publications

  • Open Access

    Vitamin K3 (Menadione) Targets TBK1 to Enhance the Efficacy of Pirfenidone in a Mouse Model of Bleomycin-Induced Pulmonary Fibrosis

    by Yanan Wang, Junxian Cao, Yingxin Zhou, Xuxia Cao, Shiwen Deng, Yu Li, Caifeng Li, Shihuan Tang, Peng Chen

    Idiopathic pulmonary fibrosis (IPF) is a progressive and irreversible interstitial lung disease. Current antifibrotic drugs, exemplified by pirfenidone (PFD), only slow disease progression with limited efficacy and adverse effects, underscoring the need for novel therapeutic strategies. By integrating single-cell transcriptomics with the Drug2Cell algorithm, we performed drug prioritization at single-cell resolution and identified menadione (vitamin K3, VK3), a synthetic naphthoquinone and the minimal core of naturally occurring vitamin K, as a candidate preferentially active in alveolar epithelial cells. In bleomycin (BLM)-stimulated A549 cells and a mouse model of pulmonary fibrosis, therapeutic co-administration of low-dose VK3 and PFD reduced vimentin expression by 44.8% and collagen deposition by 50.3%, and decreased fibroblast abundance by 36.7%, thereby attenuating histopathological damage and restoring BLM-disrupted alveolar epithelial homeostasis. Experiments with VK3 alone further demonstrated that its antifibrotic activity is independent of conversion to vitamin K2. Mechanistically, thermal proteome profiling identified TANK-binding kinase 1 (TBK1) as the principal candidate target; molecular docking and molecular dynamics simulations predicted a stable binding mode, independently confirmed by biolayer interferometry and differential scanning fluorimetry, demonstrating direct binding of VK3 to TBK1 with nanomolar affinity. TBK1 knockdown suppressed BLM-induced fibrotic responses, establishing TBK1 as a positive regulator of pulmonary fibrosis. In vitro signaling analysis revealed that VK3 plus PFD inhibits phosphorylation of TBK1 and STAT3, whereas PFD alone reduces phosphorylation of JAK1 and STAT3, suggesting that both agents converge on STAT3 through distinct upstream nodes. Although VK3 exhibits dose-dependent cytotoxicity precluding direct clinical use as monotherapy, its validated high-affinity target TBK1 and privileged naphthoquinone scaffold lay a rational foundation for lead optimization toward safer anti-IPF agents, and its ability to enhance PFD efficacy supports further development as an adjunct to existing antifibrotic therapy.

  • Open Access

    Crocins Ameliorate Experimental Immune Checkpoint Inhibitor-Related Myocarditis by Targeting the Hpx/Nrf2/HO-1 Pathway

    by Jing Yan, Qingqing Cai, Yu Li, Yi Zhang, Ye Zhao, Fangbo Zhang, Huamin Zhang

    Immune checkpoint inhibitors (ICIs) for cancer therapy may induce immune-related adverse events including myocarditis, which occurs infrequently but carries a high mortality rate. Crocins are the active constituents derived from Crocus sativus L. (saffron), and have demonstrated various bioactivities including anti-tumor, anti-inflammation, antioxidation, anti-ischemia, anti-aging, and neuroprotective effects. This study established a subcutaneous xenotransplanted tumor model of human liver cancer in nude mice to better mimic ICI-related myocarditis. Animal experimental results revealed that crocins improved cardiac function, relieved myocardial damage and autoimmune response, and suppressed oxidative stress and inflammatory reaction. Quantitative proteomics and Western blotting verification confirmed that crocins ameliorated experimental ICI-related myocarditis by targeting the Hpx/Nrf2/HO-1 pathway. Molecular docking revealed that the best docking activities were demonstrated by crocin I–HO-1, crocin II–Hpx, and crocin III–Nrf2. These findings shed new light on the development of therapeutic strategies for treating ICI-related myocarditis and provided the fundamental basis for expanding the clinical application of crocins.